AR090843A1 - Tratamiento para diabetes comorbida con enfermedad renal cronica - Google Patents
Tratamiento para diabetes comorbida con enfermedad renal cronicaInfo
- Publication number
- AR090843A1 AR090843A1 ARP130101391A AR090843A1 AR 090843 A1 AR090843 A1 AR 090843A1 AR P130101391 A ARP130101391 A AR P130101391A AR 090843 A1 AR090843 A1 AR 090843A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- renal disease
- patient
- type
- comorbid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un método para tratar la diabetes en un paciente teniendo la enfermedad renal de moderada a crónica de fase terminal que comprende la administración a dicho paciente de un compuesto de la fórmula: P-[(A)-(B)] donde: A es la cadena-A de insulina lispro (SEQ ID Nº 1); B es la cadena-B de insulina lispro (SEQ ID Nº 2); y P es PEG que tiene un peso molecular promedio de aproximadamente 17.5 kDa a cerca de 40 kDa y donde A y B son correctamente reticulados, y P es enlazado a través de un enlace covalente a la amina épsilon de la lisina en la posición 28 de B. Reivindicación 5: El método de conformidad con la reivindicación 1, caracterizado porque es de fórmula (1) donde el n promedio es de 406 a 497. Reivindicación 7: El método de conformidad con cualquiera de las reivindicaciones 1 a 6, caracterizado porque el aclarado de creatinina del paciente es menor de 60 ml/min. Reivindicación 11: El método de conformidad con cualquiera de las reivindicación 7, caracterizado porque la diabetes es diabetes tipo 1. Reivindicación 12: El método de conformidad con cualquiera de las reivindicaciones 1 a 11, caracterizado porque la diabetes es diabetes tipo 2. Reivindicación 13: El método de conformidad con cualquiera de las reivindicaciones 1 a 11, caracterizado porque la diabetes es diabetes tipo 2. Reivindicación 14: El método de conformidad con cualquiera de las reivindicaciones 1 a 13, caracterizado porque el método trata el edema inducido por insulina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644657P | 2012-05-09 | 2012-05-09 | |
| US201261651632P | 2012-05-25 | 2012-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090843A1 true AR090843A1 (es) | 2014-12-10 |
Family
ID=48468780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101391 AR090843A1 (es) | 2012-05-09 | 2013-04-25 | Tratamiento para diabetes comorbida con enfermedad renal cronica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9259479B2 (es) |
| EP (1) | EP2846837A1 (es) |
| JP (1) | JP2015517494A (es) |
| CN (1) | CN104271161A (es) |
| AR (1) | AR090843A1 (es) |
| CA (1) | CA2869184C (es) |
| HK (1) | HK1204915A1 (es) |
| TW (1) | TW201406393A (es) |
| WO (1) | WO2013169547A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107560A1 (es) | 2016-02-24 | 2018-05-09 | Lilly Co Eli | Compuesto que disminuye la glucosa en la sangre |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| EP2599502B1 (en) * | 2003-04-11 | 2017-03-01 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
| WO2008084051A1 (en) * | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mixtures of pegylated insulin and fast acting insulin for pulmonary administration |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| CN101717442A (zh) * | 2008-10-09 | 2010-06-02 | 重庆富进生物医药有限公司 | 聚乙二醇化重组人DesB30胰岛素及其制备方法和应用 |
-
2013
- 2013-04-25 AR ARP130101391 patent/AR090843A1/es unknown
- 2013-04-26 TW TW102115150A patent/TW201406393A/zh unknown
- 2013-05-02 JP JP2015511519A patent/JP2015517494A/ja not_active Withdrawn
- 2013-05-02 EP EP13724063.6A patent/EP2846837A1/en not_active Withdrawn
- 2013-05-02 WO PCT/US2013/039166 patent/WO2013169547A1/en active Application Filing
- 2013-05-02 CA CA2869184A patent/CA2869184C/en not_active Expired - Fee Related
- 2013-05-02 US US14/398,144 patent/US9259479B2/en not_active Expired - Fee Related
- 2013-05-02 CN CN201380023897.3A patent/CN104271161A/zh active Pending
-
2015
- 2015-06-05 HK HK15105383.7A patent/HK1204915A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2869184A1 (en) | 2013-11-14 |
| CN104271161A (zh) | 2015-01-07 |
| CA2869184C (en) | 2016-02-09 |
| US20150111819A1 (en) | 2015-04-23 |
| JP2015517494A (ja) | 2015-06-22 |
| US9259479B2 (en) | 2016-02-16 |
| EP2846837A1 (en) | 2015-03-18 |
| WO2013169547A1 (en) | 2013-11-14 |
| TW201406393A (zh) | 2014-02-16 |
| HK1204915A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6331292A2 (es) | Compuestos de insulina lispro pegilada | |
| MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
| AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
| CL2015001241A1 (es) | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) | |
| CY1117868T1 (el) | Νανοσωματιδια φορτωμενα με χημειοθεραπευτικο αντικαρκινικο φαρμακο | |
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| NZ626620A (en) | Enhancement of transport of therapeutic molecules across the blood brain barrier | |
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| BR112015014510A2 (pt) | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais | |
| EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
| BR112013030977A2 (pt) | composição destinada ao tratamento de diabetes, compreendendo conjugado de insulina de ação prolongada e conjugado de peptídeo insulinotrópico de ação prolongada | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| BR112013004756B1 (pt) | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 | |
| CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
| EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| AR091205A1 (es) | Farmaco para prevenir y tratar la enfermedad renal poliquistica | |
| BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
| BR112015024659A8 (pt) | formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| BR112014024358A8 (pt) | administração subcutânea de iduronato-2-sulfatase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |